Doi, Toshihiko http://orcid.org/0000-0003-2042-6829
Yoh, Kiyotaka
Shitara, Kohei
Takahashi, Hideaki
Ueno, Makoto
Kobayashi, Satoshi
Morimoto, Manabu
Okusaka, Takuji
Ueno, Hideki
Morizane, Chigusa
Okano, Naohiro
Nagashima, Fumio
Furuse, Junji
Article History
Received: 27 September 2018
Accepted: 12 November 2018
First Online: 4 December 2018
Compliance with ethical standards
:
: Toshihiko Doi has received fees for consulting or advisory role from Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Amgen Inc., Sumitomo Dainippon Pharma Co., and Taiho Pharmaceutical Co. Ltd., as well as research funding from Taiho Pharmaceutical Co. Ltd., Novartis Pharma K.K., Merck Serono Co., Ltd., Astellas Pharma Inc., MSD K.K., Janssen Pharmaceutical K.K., Nippon Boehringer Ingelheim Co., Takeda Pharmaceuticals, Pfizer Inc., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Celgene Corporation, Bristol-Myers Squibb, AbbVie Inc., and Quintiles IMS Holdings, Inc. Kiyotaka Yoh has received grants and personal fees from Taiho Pharmaceutical, during the conduct of the study; grants and/or personal fees from Chugai Pharmaceutical Co., AstraZeneca K.K., Eli Lilly Japan, K.K., Boehringer Ingelheim Co., Ono Pharmaceutical Co., Novartis Pharma K.K., Bayer Yakuhin, Ltd., Pfizer Inc., MSD K.K., Bristol-Myers Squibb, in relation to work other than that submitted here. Kohei Shitara has received grants and/or personal fees from Astellas Pharma Inc., Eli Lilly Japan K.K., Bristol-Myers Squibb, Takeda Pharmaceuticals, Pfizer Inc., Ono Pharmaceutical Co., Novartis Pharma K.K., AbbVie Inc., Yakult Honsha Co., Ltd., Sumitomo Dainippon Pharma Co., Daiichi Sankyo Co., Taiho Pharmaceutical Co., Chugai Pharmaceutical Co., MSD K.K in relation to work other than that submitted here. Hideaki Takahashi has received honoraria from Taiho Pharmaceutical Co., Bayer Yakuhin, Ltd., and Torii Pharmaceutical Co. Ltd., as well as research funding from Bristol-Myers Squibb and Bayer Yakuhin, Ltd. Makoto Ueno has received honoraria from Taiho Pharmaceutical Co., Yakult Honsha Co., Ltd., AstraZeneca K.K., Novartis Pharma K.K., Eli Lilly Japan K.K., Teijin Pharma, Ltd., Shire Plc, Ono Pharmaceutical Co., received fees consulting or advisory role from Eisai Co., and research funding from Taiho Pharmaceutical Co., Shire Plc, Daiichi Sankyo Co., Eisai Co., AstraZeneca K.K., Ono Pharmaceutical Co., MSD K.K., Merck Serono Co., Ltd., NanoCarrier, Co., Ltd., Sumitomo Dainippon Pharma Co., and Incyte Corp. Satoshi Kobayashi received honoraria from Taiho Pharmaceutical Co., Yakult Honsha Co., Ltd., AstraZeneca K.K., Boston Scientific Corp., Merck Serono Co., Nippon Kayaku Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Daiichi Sankyo Co., Bayer Yakuhin, Ltd., a speaker’s bureau from Kyowa Hakko Kirin Co., research funding from Taiho Pharmaceutical Co., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Chugai Pharmaceutical Co., and Yakult Honsha Co., Ltd., and travel, accommodation, and expenses reimbursement from Novartis Pharma K.K. Manabu Morimoto has received honoraria from Bayer Yakuhin, Ltd., Eisai Co., Ltd., and Nippon Kayaku Co., Ltd., as well as research funding from Bayer Yakuhin, Ltd., Yakult Honsha Co., Ltd., Shionogi & Co., Ltd., and Eli Lilly Japan K.K. Takuji Okusaka has received honoraria, fees for consulting or advisory role, or research funding from Novartis Pharma K.K., Taiho Pharmaceutical Co. Ltd., Merck Serono Co., Ltd., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Ltd., Bayer Yakuhin, Ltd., Yakult Honsha Co., Ltd., Nobelpharma Co., Ltd., Nippon Kayaku Co., Ltd., Baxter Limited, FUJIFILM RI Pharma Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Nippon Chemiphar Co., Ltd., Celgene, K.K., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kowa company, Ltd., Kyowa Hakko Kirin Co., Ltd., Glaxo Smith Kline K.K., Shizuoka Industry Nano Carrier Co., Ltd., and Pfizer Japan Inc. Hideki Ueno has received honoraria and research funding from Taiho Pharmaceutical Co., Ltd. Chigusa Morizane has received honoraria from Pfizer Inc., Novartis Pharma K.K., Yakult Honsha Co., Ltd., Nobelpharma Co., Ltd., Eli Lilly Japan K.K., and FUJIFILM RI Pharma Co., Ltd., fees for consulting or advisory role from Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., and Novartis Pharma K.K., and research funding from Yakult Honsha Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Taiho Pharmaceutical Co. Ltd., and Pfizer Inc. Naohiro Okano has received honoraria from Taiho Pharmaceutical Co. Ltd. and Merck Serono Co., Ltd. Fumio Nagashima has received research funding from Taiho Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Sanofi K.K., MSD K.K., Eisai Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd. Junji Furuse has received honoraria from Taiho Pharmaceutical Co. Ltd., Yakult Honsha Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly Japan K.K., Astellas Pharma Inc., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Bayer Yakuhin, Ltd., Novartis Pharma K.K., Merck Serono Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceuticals, Nippon Kayaku Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Sawai Pharmaceutical Co., Ltd., and MSD K.K.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.